ArticleHead & face medicine2026
m⁶A-Modified hsa_circ_0002694 facilitates OSCC progression via the METTL14/YTHDC1/miR-616-3p/c-Myc axis.
Article in Head & face medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) is an aggressive malignancy with poor prognosis and limited therapeutic options. N6-methyladenosine (m⁶A) modification has emerged as a key regulator of RNA fate, including circular RNAs (circRNAs), yet the functional contribution of m⁶A-modified circRNAs to OSCC remains incompletely defined. Here, we characterized hsa_circ_0002694, a previously unannotated circRNA, and investigated its m⁶A-associated regulatory mechanism in OSCC. We found that hsa_circ_0002694 was markedly upregulated in OSCC tissues and cell lines. Loss-of-function assays showed that hsa_circ_0002694 silencing inhibited OSCC cell proliferation, migration, and invasion in vitro and suppressed xenograft tumor growth in vivo. Mechanistically, METTL14-dependent m⁶A modification supported hsa_circ_0002694 abundance and enabled recognition/association by the nuclear m⁶A reader YTHDC1, contributing to its stability and nuclear retention/distribution. In the cytoplasm, hsa_circ_0002694 functioned as a competing endogenous RNA by sequestering miR-616-3p, thereby de-repressing METTL14 and reinforcing a putative positive feedback loop. In parallel, METTL14 increased m⁶A enrichment on MYC transcripts and, together with the m⁶A reader YTHDF1, promoted c-Myc protein expression, linking the circRNA circuit to an established oncogenic driver in OSCC. RNA immunoprecipitation, MeRIP-PCR, and RNA pull-down assays supported the m⁶A-associated regulatory relationships among hsa_circ_0002694, METTL14, YTHDC1, and miR-616-3p. Collectively, our findings define an m⁶A-regulated hsa_circ_0002694-centered network that connects METTL14/YTHDC1 control of circRNA fate with miR-616-3p-mediated de-repression and METTL14/YTHDF1-dependent c-Myc upregulation, providing mechanistic insight into epitranscriptomic circRNA regulation in OSCC and suggesting hsa_circ_0002694 as a potential biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.